🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
547,09 USD
Máx. histórico
558,88
7 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,11%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+0,85%
Cierre anterior
542,50
Rango de hoy
531,53 – 548,76
Volumen hoy
1.271.214
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 35,21 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 2 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 11/01/2005 | 11,00 | 11,10 | 10,73 | 10,92 | +1,30% | 3,36% | 1.049.600 |
| 10/01/2005 | 10,95 | 11,19 | 10,71 | 10,78 | +2,76% | 4,38% | 871.900 |
| 07/01/2005 | 10,68 | 10,74 | 10,25 | 10,49 | -0,29% | 4,59% | 609.100 |
| 06/01/2005 | 10,12 | 10,68 | 9,97 | 10,52 | +6,26% | 7,02% | 1.108.000 |
| 05/01/2005 | 10,12 | 10,20 | 9,88 | 9,90 | -1,88% | 3,16% | 1.063.200 |
| 04/01/2005 | 10,16 | 10,28 | 9,90 | 10,09 | -1,46% | 3,74% | 908.300 |
| 03/01/2005 | 10,70 | 10,71 | 10,08 | 10,24 | -3,12% | 5,89% | 776.900 |
| 31/12/2004 | 10,73 | 10,80 | 10,50 | 10,57 | -1,67% | 2,80% | 736.400 |
| 30/12/2004 | 10,86 | 10,86 | 10,67 | 10,75 | -0,92% | 1,75% | 341.200 |
| 29/12/2004 | 10,84 | 10,91 | 10,53 | 10,85 | -0,18% | 3,51% | 589.200 |
| 28/12/2004 | 10,69 | 10,92 | 10,68 | 10,87 | +1,12% | 2,25% | 487.400 |
| 27/12/2004 | 10,81 | 11,00 | 10,57 | 10,75 | -1,65% | 3,98% | 532.800 |
| 23/12/2004 | 10,90 | 11,10 | 10,75 | 10,93 | +0,46% | 3,21% | 379.100 |
| 22/12/2004 | 10,99 | 11,04 | 10,80 | 10,88 | -0,73% | 2,18% | 440.600 |
| 21/12/2004 | 10,87 | 11,04 | 10,75 | 10,96 | +0,46% | 2,67% | 587.500 |
| 20/12/2004 | 11,28 | 11,28 | 10,62 | 10,91 | -3,19% | 5,85% | 1.068.100 |
| 17/12/2004 | 11,31 | 11,33 | 11,03 | 11,27 | -0,97% | 2,65% | 626.500 |
| 16/12/2004 | 11,51 | 11,51 | 11,25 | 11,38 | -0,70% | 2,26% | 483.300 |
| 15/12/2004 | 11,49 | 11,50 | 11,11 | 11,46 | -0,09% | 3,39% | 722.400 |
| 14/12/2004 | 11,25 | 11,50 | 11,19 | 11,47 | +1,77% | 2,76% | 689.300 |
| 13/12/2004 | 10,95 | 11,27 | 10,88 | 11,27 | +3,58% | 3,56% | 330.600 |
| 10/12/2004 | 10,92 | 11,05 | 10,71 | 10,88 | +0,09% | 3,11% | 352.700 |
| 09/12/2004 | 10,82 | 10,97 | 10,65 | 10,87 | -0,55% | 2,96% | 473.100 |
| 08/12/2004 | 10,57 | 11,05 | 10,49 | 10,93 | +3,90% | 5,30% | 467.100 |
| 07/12/2004 | 11,26 | 11,30 | 10,51 | 10,52 | -6,24% | 7,02% | 483.200 |
| 06/12/2004 | 11,17 | 11,38 | 10,91 | 11,22 | +0,72% | 4,21% | 432.700 |
| 03/12/2004 | 11,12 | 11,25 | 10,75 | 11,14 | +0,63% | 4,50% | 364.600 |
| 02/12/2004 | 10,77 | 11,14 | 10,45 | 11,07 | +3,36% | 6,41% | 669.900 |
| 01/12/2004 | 10,61 | 10,80 | 10,50 | 10,71 | +0,85% | 2,83% | 913.800 |
| 30/11/2004 | 10,46 | 10,71 | 10,33 | 10,62 | +1,92% | 3,63% | 652.500 |